MML Investors Services LLC Sells 613 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

MML Investors Services LLC decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.4% during the third quarter, HoldingsChannel reports. The fund owned 13,451 shares of the medical research company’s stock after selling 613 shares during the quarter. MML Investors Services LLC’s holdings in Charles River Laboratories International were worth $2,649,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in CRL. State Street Corp boosted its position in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Quest Partners LLC lifted its stake in Charles River Laboratories International by 135,175.0% in the 2nd quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock worth $1,118,000 after purchasing an additional 5,407 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock valued at $22,060,000 after purchasing an additional 3,714 shares during the period. Janus Henderson Group PLC grew its position in shares of Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after purchasing an additional 3,268 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Charles River Laboratories International by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after purchasing an additional 32,311 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $190.46 on Monday. The firm has a fifty day simple moving average of $194.35 and a two-hundred day simple moving average of $202.96. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The company has a market capitalization of $9.74 billion, a PE ratio of 23.84, a P/E/G ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.72 earnings per share. Research analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent analyst reports. Evercore ISI boosted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Robert W. Baird cut their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their target price for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. TD Cowen boosted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Finally, Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).